Evidence map›Paper›PMID 42848122›Full record

ReviewJournal of natural medicines2026

Plant-derived phytochemicals for Alzheimer's disease: mechanisms of action, experimental evidence, and therapeutic perspectives.

Janhavi Nimbalkar, Rushikesh Shinde

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Janhavi Nimbalkar *Department of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy, Thergaon (Kalewadi), Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, 411033, India.
Rushikesh Shinde *Department of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy, Thergaon (Kalewadi), Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, 411033, India. rushikesh.shinde@mmcop.edu.in.ORCID http://orcid.org/0009-0003-0304-3057

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by cholinergic deficits, amyloid-beta accumulation, tau hyperphosphorylation, oxidative stress, neuroinflammation, and synaptic dysfunction, which collectively contribute to cognitive decline and neuronal loss. Conventional pharmacotherapies provide symptomatic relief but largely target single pathological pathways, highlighting the need for multi-targeted approaches. Herbal therapeutics have emerged as promising complementary or alternative interventions, offering multifaceted mechanisms that simultaneously modulate key disease processes. Preclinical studies, including in vitro and animal models, indicate that extracts of medicinal plants, including Bacopa monnieri (aerial parts), Ginkgo biloba (leaves), Curcuma longa (rhizomes), and Withania somnifera (roots), may enhance cognitive function, exert neuroprotective effects, attenuate oxidative stress and inflammation, and modulate amyloid and tau pathology. However, clinical evidence remains limited, heterogeneous, and inconclusive, with existing studies reporting variable effects on memory, attention, executive function, and global cognition and generally providing only preliminary evidence of safety and efficacy. This translational gap is further influenced by poor bioavailability and brain delivery of several phytoconstituents, variability in herbal preparations, inadequate standardisation, differences in dosing and study design, and the scarcity of adequately powered, long-term clinical trials. Emerging approaches, including nanotechnology-based delivery systems, rational combinations with conventional therapeutics or complementary herbal agents, and personalised interventions based on genetic and metabolic characteristics, may improve therapeutic precision and clinical translation. Integrating mechanistic insights with experimental and clinical evidence may help identify the most promising herbal candidates while defining their translational limitations. This review synthesises current evidence and future directions, providing a framework for advancing herbal interventions in AD.

Indexed as

Acetylcholinesterase inhibitionAlzheimer’s diseaseMedicinal plantsMulti-target therapyNeuroinflammationNeuroprotectionOxidative stressPhytochemicals

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.